CJC-1295 DAC 5mg Dosage Protocol | PeptideDosages.com

CJC-1295 DAC (5 mg Vial) Dosage Protocol

CJC-1295 DAC Dosage Chart

CJC-1295 DAC is dosed at 300 mcg–1 mg weekly via subcutaneous injection in educational protocols. A 5 mg vial reconstituted with bacteriostatic water yields about 2.5 mg/mL. This information is for research and educational use only.

Reconstitute: Add 2.0 mL bacteriostatic water → 2.5 mg/mL (2500 mcg/mL) concentration.

Typical dose range: 300–1000 mcg per injection, twice weekly (gradual titration).

Easy measuring: At 2.5 mg/mL, 1 unit = 0.01 mL = 25 mcg on a U-100 insulin syringe.

Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

CJC-1295 DAC is a long-acting synthetic analog of growth hormone-releasing hormone (GHRH). The DAC (Drug Affinity Complex) modification binds reversibly to albumin, extending the peptide’s half-life to approximately 6–8 days[1]. By stimulating pituitary GHRH receptors, CJC-1295 DAC increases GH secretion and circulating IGF-1 in a dose-dependent manner[2]. This educational protocol presents a twice-weekly subcutaneous approach using a practical dilution for clear insulin-syringe measurements.

Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety, read CJC-1295 DAC Peptide: Benefits, Uses, Side Effects, Dosage, and Research.

Standard / Gradual Approach (2 mL = 2500 mcg/mL)

Weeks 1–2

300 mcg (0.3 mg)

12 units (0.12 mL)

600 mcg/week

Weeks 3–4

500 mcg (0.5 mg)

20 units (0.20 mL)

1000 mcg/week

Weeks 5–6

750 mcg (0.75 mg)

30 units (0.30 mL)

1500 mcg/week

Weeks 7–12

1000 mcg (1 mg)

40 units (0.40 mL)

2000 mcg/week

Frequency: Inject twice weekly subcutaneously (e.g., Monday/Thursday or Tuesday/Friday). The extended 6–8-day half-life from the DAC modification supports less frequent dosing compared to non-DAC GHRH analogs[1][2]. Once-weekly dosing is also studied; adjust frequency based on protocol requirements.

For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.

Reconstitution Steps

Draw 2.0 mL bacteriostatic water with a sterile syringe.

Inject slowly down the vial wall; avoid foaming.

Gently swirl/roll until dissolved (do not shake).

Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Supplies Needed

Plan based on an 8–16 week twice-weekly protocol with gradual titration.

Peptide Vials (CJC-1295 DAC, 5 mg each):

8 weeks ≈ 3 vials (~10.2 mg total)

12 weeks ≈ 4 vials (~18.2 mg total)

16 weeks ≈ 6 vials (~26.2 mg total)

Insulin Syringes (U-100):

Per week: 2 syringes (twice weekly)

8 weeks: 16 syringes

12 weeks: 24 syringes

16 weeks: 32 syringes

Bacteriostatic Water (10 mL bottles): Use ~2.0 mL per vial for reconstitution.

8 weeks (3 vials): 6 mL → 1 × 10 mL bottle

12 weeks (4 vials): 8 mL → 1 × 10 mL bottle

16 weeks (6 vials): 12 mL → 2 × 10 mL bottles

Alcohol Swabs: One for the vial stopper + one for the injection site each injection.

Per week: 4 swabs (2 per injection × 2 injections)

8 weeks: 32 swabs → recommend 1 × 100-count box

12 weeks: 48 swabs → recommend 1 × 100-count box

16 weeks: 64 swabs → recommend 1 × 100-count box